• Issue
    Volume 125, Issue S24
    4557-4629
    15 December 2019

Issue Information

Free Access

Issue Information

  • Pages: 4557-4562
  • First Published:03 December 2019

Review Articles

Free Access

Biomarkers in ovarian cancer: To be or not to be

  • Pages: 4563-4572
  • First Published:03 December 2019

Biomarkers for ovarian cancer have evolved into clinical significance. They are proposed to help in streamlining therapeutic interventions to improve clinical outcomes and the quality of life for all patients.

Free Access

How to manage lymph nodes in ovarian cancer

  • Pages: 4573-4577
  • First Published:03 December 2019

Lymph node dissection and its implications in early and advanced ovarian cancer are discussed.

Free Access

Can we predict who lives long with ovarian cancer?

  • Pages: 4578-4581
  • First Published:03 December 2019

This article provides an overview of predictive models and nomograms for women with ovarian cancer. Limitations of current models and future directions are discussed.

Free Access

Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy

  • Pages: 4582-4586
  • First Published:03 December 2019

The backbone of systemic chemotherapy for advanced ovarian cancer remains the combination of paclitaxel and carboplatin. However, the incorporation of poly(adenosine diphosphate–ribose) polymerase inhibitors as a maintenance therapy has been dramatically changing the landscape.

Free Access

Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on

  • Pages: 4587-4593
  • First Published:03 December 2019

This review discusses the design and results of a phase 3 randomized trial in HIPEC for patients with ovarian cancer (OVHIPEC trial; NCT00426257). The evidence that is currently available points to a clinically relevant and cost-effective benefit of hyperthermic intraperitoneal chemotherapy added to interval cytoreductive surgery for patients with stage III ovarian cancer who are not eligible for primary surgery.

Free Access

Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer

  • Pages: 4594-4597
  • First Published:03 December 2019

Data about hyperthermic intraperitoneal chemotherapy in ovarian cancer in general are not convincing and do not change the standard of care, which remains for ovarian cancer surgery and intravenous chemotherapy.

Open Access

Surgery in recurrent ovarian cancer

  • Pages: 4598-4601
  • First Published:03 December 2019

Surgery is an option in recurrent ovarian cancer. The selection of patients with recurrent ovarian cancer who may profit from a surgical approach remains crucial.

Free Access

Do all patients with recurrent ovarian cancer need systemic therapy?

  • Pages: 4602-4608
  • First Published:03 December 2019

There is complex interplay between patient-associated and tumor-associated factors that impacts the likelihood of a response to systemic therapies and prognosis in patients with advanced ovarian cancer. These factors should be considered to help avoid futile treatment, particularly in the final weeks of life.

Free Access

Treatment of recurrent epithelial ovarian cancer

  • Pages: 4609-4615
  • First Published:03 December 2019

The treatment of ovarian cancer recurrence is changing. Drugs targeting angiogenesis or the mechanisms of DNA repair have been added to chemotherapy for patients who are candidates to receive platinum again. Patients who are not candidates for platinum should receive single-agent chemotherapy and bevacizumab if they have not previously been treated with the drug in the first line.

Free Access

Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?

  • Pages: 4616-4622
  • First Published:03 December 2019

Clinical data regarding the use of checkpoint inhibitors (CPIs) as monotherapy have not been very convincing to date. The highest expectation currently is focused on the combination of CPIs with antiangiogenic agents and/or poly(adenosine diphosphate–ribose) polymerase inhibitors and the search for better biomarkers in the selection of patients.

Free Access

New strategies in ovarian cancer treatment

  • Pages: 4623-4629
  • First Published:03 December 2019

New strategies are needed to identify novel approaches for the treatment of ovarian cancer. In this article, 6 approaches are discussed.